 NEWTON, Mass., Aug. 04, 2020 GLOBE NEWSWIRE -- Allena Pharmaceuticals, Inc. NASDAQ: ALNA, a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allenas President and Chief Executive Officer, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020, at 8:35 a.m. ET. A live audio webcast of the presentation will be available under Events and Presentations in the Investors section of the Companys website at A replay of the webcast will be available on the Allena website for 30 days following the presentation.About Allena Pharmaceuticals Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allenas lead product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 Contact Adam Daley Berry Company Public Relations 212-253-8881 